Kadmon Doses First Patient in Open-Label Phase 2 Clinical Trial of Belumosudil in Systemic …,

(NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company’s ROCK2 …, (NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company’s ROCK2 …, Read More

Scroll to Top